Question 1

Which GLP-1 medicines can actually be prescribed?

Accepted Answer

Three molecules carry that status for weight loss. A 2025 review of real-world evidence works from the currently approved GLP-1RA-based weight-loss therapies, that is, liraglutide, semaglutide and tirzepatide. The short form GLP-1 RA, used throughout the literature, simply means a GLP-1 receptor agonist. A 2025 analysis of the regulator's safety database reaches wider. It queried events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023. That is five molecules with five separate approvals, all sitting under one class name. One of the five is not purely a GLP-1 agonist. A 2025 comparative review records that Semaglutide is a GLP-1 receptor agonist, while Tirzepatide acts as a dual agonist for the GLP-1 and GIP receptors. The distinction matters at the counter, because a box can say GLP-1 and hold either kind of molecule.

Question 2

Why is GLP-1 a class name rather than a medicine?

Accepted Answer

The class is older and wider than the two names that rule the market. A 2019 pooling of heart-outcome trials gathered seven of them: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide). Seven trials, seven molecules, one shared family name. The same work notes that these agents differ in their structure and duration of action. They are not swaps for one another, and a result from one of them does not pass to the next by family likeness. A completed phase 3 study of the GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes sits on the public trials register. Hardly anyone types that name into a search box. Two names in this class are famous, and the rest are ones most buyers have never seen.

Question 3

Can you buy GLP-1 pills over the counter?

Accepted Answer

There is a GLP-1 tablet, and it is a prescription medicine rather than something on a shelf. The PIONEER 1 trial tested the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, in adults with type 2 diabetes. Those adults were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. So a GLP-1 in tablet form exists, it has completed a phase 3a trial, and it reaches a person the same way the weekly injections do. No source among the research behind this page examines a GLP-1 pill sold over a counter. That is an absence of measurement rather than a measurement of absence, and it is why this page describes what was tested rather than what is on sale.

Question 4

What does the oral GLP-1 record actually cover?

Accepted Answer

Two quite different things get called an oral GLP-1, and only one of them has a label. The first is oral semaglutide, the same peptide rebuilt as a tablet. A 2025 review of semaglutide notes the availability of both subcutaneous and oral formulations for patients. The second is a new chemical class. A 2025 phase 3 report says orforglipron is being investigated as a treatment for obesity. A second 2025 report describes that same molecule as in clinical development for type 2 diabetes and weight management. Those are careful phrases, and they mean a medicine under test rather than one a reader can be handed. A 2022 review of diabetes care made the point from the other side, noting that oral delivery has already been achieved for incretins. Incretins are the gut hormones this class copies: a 2025 review calls GIP and GLP-1 the two gut-derived incretin hormones.

Question 5

What about GLP-1 patches, drops and gummies?

Accepted Answer

They are absent from the record. No source among the research behind this page examines a GLP-1 patch, an oral drop or a gummy sold under the class name. That is a plain gap, and it is worth stating plainly rather than filling with inference. What the record does cover is narrow and specific. The 2025 real-world review is about the currently approved GLP-1RA-based weight-loss therapies, that is, liraglutide, semaglutide and tirzepatide. The 2025 registry analysis is about the same kind of material, and the Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for five named molecules. Both the published literature and the regulator's records are therefore built around prescription medicines with a named molecule inside. A patch or a gummy sits outside both. Sitting outside them is not a verdict on whether it does anything; it means no study among the research behind this page has published a measurement in either direction.

Question 6

What is a GLP-1 supplement meant to do?

Accepted Answer

Capsules and powders sold under the class name usually claim to raise the GLP-1 your own gut makes, rather than to supply a receptor agonist. No source among the research behind this page tests that claim in people, so there is no published figure to report in either direction. The published work describes something else. A 2025 mechanism review reports that, centrally, these agents modulate brain regions controlling appetite, influencing neurotransmitter and peptide release to regulate hunger and energy expenditure in patients with obesity and type 2 diabetes. Read that carefully, because it describes a prescribed molecule occupying a receptor, not a capsule nudging a hormone. Those are different questions, and the trials behind this class have only asked the first.

Question 7

Are GLP-1 medicines injected or swallowed?

Accepted Answer

Both, depending on the molecule, and the route is part of what was tested. In the STEP 7 trial, adults with overweight or obesity were randomly assigned (2:1) to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks. Subcutaneous means under the skin. A 2024 network meta-analysis put the two best-known molecules side by side, weighing s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. Older members of the class were daily injections. A randomised trial of weight-loss maintenance ran for a year on the GLP-1 RA liraglutide 3.0 mg/day in adults with obesity. Route, amount and schedule travel with a published result, and a container bought under the class name carries none of the three.

Question 8

How much does a GLP-1 cost?

Accepted Answer

No figure for that appears among the research behind this page, and we do not collect information. Prices move weekly and differ by pharmacy, so a number printed on a page of this kind is stale before anybody reads it. Cost does appear in the literature, but as a reason people stop. A 2025 review of real-world evidence records that many patients stop using them within the first year due to side effects or high costs of the medications, especially if not covered by insurance. That is a finding about patients, rather than a price list. What a price is attached to is the checkable part. An approved injection or tablet carries an identified molecule, an identified manufacturer, an approved label and a published trial record. A compounded vial carries the molecule name and no approved label. Comparing the two on price alone compares two different commodities rather than one commodity twice.

Question 9

What is the cheapest GLP-1 without insurance?

Accepted Answer

No source among the research behind this page reports what any of these medicines cost, with or without insurance. Nobody assembles that information in a form a reader could independently check, so a cheapest answer would be guesswork wearing a number. The same 2025 real-world review does record what surrounds the price. Real-world studies demonstrate high discontinuation rates of GLP-1RAs (20%-50%) within the first year, and the use of much lower doses than those evaluated in clinical trials. The second half of that sentence is the part worth sitting with. An amount lower than the trials assigned is a different exposure from the one the published results came out of, so a cheaper course and a published figure describe different situations rather than an identical situation at two prices.

Question 10

Does a cheaper GLP-1 mean the same medicine?

Accepted Answer

Not necessarily, and the class name is where that ambiguity lives. The 2019 pooling notes that these agents differ in their structure and duration of action. Two containers both labelled GLP-1 can hold entirely different molecules on different schedules. A price can also differ because the amount inside differs. A 2025 trial in early type 2 diabetes assigned adults to orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. That is a twelvefold span of amount inside a single molecule and a single trial. So a lower price can mean a different molecule, a smaller amount, a compounded vial, or material with no label at all. Those are four separate situations rather than one, and telling them apart starts with reading what the container names.

Question 11

What is a compounded GLP-1, and what does it carry?

Accepted Answer

A compounded vial is made up by a pharmacy rather than by the holder of an approval, and carries no approved label. What has been shown for an approved injection has not been shown for it. The published trial figures belong to the material those trials used. No source among the research behind this page examines compounded material of any kind. What it examines is approved and investigational medicines: the currently approved GLP-1RA-based weight-loss therapies, and a molecule in clinical development for type 2 diabetes and weight management. Compounding sits outside that record rather than inside it. That question gets answered one molecule at a time, since a recall names a firm and a vial rather than a class. Our sourcing pages for semaglutide and for tirzepatide set out the recall entries the Food and Drug Administration has published for each.

Question 12

What can you actually check before buying?

Accepted Answer

Four things can be established at class level, and none of them requires trusting anybody. The first is which molecule is being sold, by name, since the class holds at least seven. The second is whether that molecule holds an approval. A 2025 real-world review names liraglutide, semaglutide and tirzepatide as currently approved GLP-1RA-based weight-loss therapies, and anything outside that list is either investigational or unapproved. The third is the route and the amount, since every published result is tied to both. The fourth is whether a prescription is involved, the line between the supply route with a documented record and the routes with none. A verdict on a named seller appears in no source among the research behind this page, so a page offering one is improvising. A method survives a change of supplier rather than going stale.

Question 13

What does the name on the box tell you?

Accepted Answer

Far more than the class name does, if a reader reads it. A box can describe three quite different kinds of molecule, and only the first is a plain GLP-1 receptor agonist. The second kind is a co-agonist. A 2025 mechanism review describes emerging dual and triple co-agonists, targeting GLP-1 alongside glucose-dependent insulinotropic polypeptide, and glucagon pathways. One of them stretches the label a long way: LY3437943 is a novel triple agonist peptide at the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). The third kind is a pairing with something from outside the class. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide, according to a 2024 account of it. Amylin is a separate hormone, so an amylin analogue is not a GLP-1 at all, and a buyer reading only the class name would be seeing half the molecule rather than all of it.

Question 14

Why does the trial material matter to a purchase?

Accepted Answer

Every number published about this class came out of a defined assignment under a written protocol. In the SURPASS-1 trial, participants were randomly assigned (1:1:1:1) via computer-generated random sequence to once a week tirzepatide (5, 10, or 15 mg), or placebo. The obesity trial of the oral agonist ran the same way, with adults given once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo. Those conditions are part of the result rather than wrapping around it: the material was made to a filed specification, the amount and the schedule were fixed, and somebody counted what happened. A container bought under the class name shares a word with all of that. Whether it shares a molecule, an amount or a manufacturing standard is a separate question, and a laboratory report on one batch is the only document that starts to answer it.

Sourcing GLP-1: what to verify